BMO Capital Maintains The Chemours(CC.US) With Buy Rating, Cuts Target Price to $17
Jefferies Maintains The Chemours(CC.US) With Hold Rating, Cuts Target Price to $11.5
Chemours Is Maintained at Outperform by RBC Capital
Express News | Chemours : BMO Cuts Target Price to $17 From $21
RBC Cuts Price Target on Chemours to $14 From $17, Keeps Outperform Rating
The Chemours Co (CC) Q1 2025 Earnings Call Highlights: Navigating Challenges With Strategic ...
Truist Financial Maintains The Chemours(CC.US) With Buy Rating
UBS Maintains The Chemours(CC.US) With Buy Rating, Cuts Target Price to $17
Mizuho Securities Maintains The Chemours(CC.US) With Buy Rating, Cuts Target Price to $13
Research Alert: CFRA Keeps Strong Sell Opinion On Shares Of The Chemours Company
New Analyst Forecast: $CC Given $17.0 Price Target
6 Analysts Assess Chemours: What You Need To Know
Chemours Outlines 2025 Adjusted EBITDA Guidance at $825M-$950M Amid Opteon Growth and Cost Reductions
Express News | Chemours Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Adjusted EPS Results. Also, UBS Lowered Its Price Target on the Stock From $18 to $17
Chemours Is Maintained at Buy by UBS
Chemours Analyst Ratings
Express News | Chemours : Mizuho Cuts Target Price to $13 From $15
Express News | Shares of Chemours Down 11.4% Premarket After Co Cuts FY Core Profit Outlook
Chemours Cuts Dividend by 65% to $0.0875
Alembic Global Maintains The Chemours(CC.US) With Buy Rating, Cuts Target Price to $18